RegulatoryJul 7, 2026, 08:51 AM
BIO-key Regains Nasdaq Compliance; Trading Resumes July 8
AI Summary
BIO-key International, Inc. announced that its common stock trading will recommence on the Nasdaq Capital Market effective July 8, 2026. The company regained compliance with Nasdaq's continued listing standards, including minimum bid price and SEC filing requirements, following a hearing with a Nasdaq Hearings Panel. CEO Michael DePasquale expressed optimism, citing growing recurring revenue, a solid financial position, and expectations for significantly improved results this year.
Key Highlights
- BIO-key common stock trading to recommence on Nasdaq Capital Market.
- Trading resumption effective Wednesday, July 8, 2026.
- Company regained compliance with Nasdaq's minimum bid price and SEC filing requirements.
- Subject to a Discretionary Panel Monitor until July 6, 2027.
- CEO expressed gratitude to Nasdaq and highlighted growing recurring revenue.
- CEO expects significantly improved results for the current year.
Price Impact
More from BKYI